Daily Anesthesiology Research Analysis
Analyzed 86 papers and selected 3 impactful papers.
Summary
Three impactful anesthesiology-related studies span safety, risk stratification, and analgesic optimization: (1) a translational report links a specific mitochondrial DNA variant to sevoflurane hypersensitivity with mechanistic validation; (2) a comprehensive PRISMA-guided meta-analysis refines predictors of postanesthesia apnea in infants and supports neuraxial techniques; and (3) a network meta-analysis identifies NMDA receptor antagonists—particularly esketamine and dextromethorphan—as promising options for reducing acute postoperative pain and opioid needs.
Research Themes
- Anesthetic pharmacogenetics and perioperative safety
- Infant postanesthesia apnea risk stratification and monitoring
- NMDA receptor antagonist strategies for acute postoperative pain
Selected Articles
1. Effects of a Mitochondrial Genetic Variant on Sevoflurane Hypersensitivity.
A shared mtDNA haplotype containing the m.11232T>C (ND4 L158P) variant was identified in seven patients with severe perioperative neurologic deterioration temporally associated with anesthesia; deterioration did not occur with purely intravenous anesthetics in some individuals. In vitro, sevoflurane—but not propofol—preferentially suppressed complex I-dependent respiration in variant-carrying cells, pointing to a mitochondrial pharmacogenetic risk.
Impact: This study identifies a concrete mitochondrial genetic variant that mechanistically confers sevoflurane vulnerability, integrating clinical observations with cybrid-based functional assays.
Clinical Implications: Consider targeted genetic evaluation or heightened caution in patients from high-risk populations or with suggestive family histories; favor intravenous anesthetic strategies if risk is suspected and ensure postoperative neurologic vigilance.
Key Findings
- All seven affected patients shared a mtDNA haplotype carrying m.11232T>C (ND4 L158P).
- Sevoflurane exposure markedly suppressed complex I–dependent mitochondrial respiration in variant-harboring cells; propofol did not show this differential effect.
- Some individuals had no adverse events when anesthesia was exclusively intravenous, implicating inhalational agents in risk expression.
Methodological Strengths
- Integration of clinical genetics with mechanistic validation using patient-derived fibroblasts and cybrids.
- Agent-specific functional testing directly comparing sevoflurane and propofol effects on mitochondrial respiration.
Limitations
- Small sample size (n=7) and observational nature limit generalizability.
- No prospective screening or anesthetic-specific risk quantification in larger cohorts.
Future Directions: Prospective multicenter studies to define prevalence and penetrance of the variant, establish anesthetic-specific risk, and develop perioperative screening algorithms.
BACKGROUND: Recently, various anesthesiology societies have reported cases involving pediatric patients of Venezuelan origin who underwent surgery under general anesthesia and subsequently developed serious neurologic impairment or died. However, the cause of this condition was unknown. METHODS: Clinical and genetic studies were conducted on seven patients who experienced severe acute neurologic deterioration after the administration of general anesthetics during predominantly minor surgical procedures. Genetic-molecular, biochemical, and cellular studies were also performed on fibroblasts and cybrids treated with general anesthetics. RESULTS: In our cohort, acute perioperative events were observed in temporal association with anesthetic exposure. No adverse events were observed in a subset of the same individuals when only intravenous anesthesia was used. All patients shared a mitochondrial DNA haplotype that includes the m.11232T>C genetic variant, which results in the substitution of proline for leucine at position 158 (L158P) of the ND4 subunit of respiratory complex I in the electron transport chain. In vitro studies showed that sevoflurane exposure in cells carrying this genetic variant induces a pronounced suppression of mitochondrial oxygen consumption, with prominent effects on complex I-dependent respiratory pathways. In contrast, propofol did not elicit a differential effect in cells harboring this genetic variant. CONCLUSIONS: These findings suggest that individuals carrying the m.11232T>C mitochondrial DNA variant may be at increased risk of severe neurologic deterioration after exposure to anesthetic agents. Further studies are needed to define the underlying mechanisms and to determine anesthetic-specific risks. These results have important implications for improving the safety of surgical interventions and open new avenues in the field of mitochondrial pharmacogenetics of general anesthesia.
2. Postanesthesia Apnea in Former Preterm and Term Infants: A Qualitative Systematic Review and Meta-analysis.
This PRISMA-guided review (115 studies) found a median postanesthesia apnea incidence of 7.6% and identified postmenstrual age as the strongest predictor. Meta-regression suggested neuraxial anesthesia reduces apnea odds versus general anesthesia, and monitoring recommendations range 6–24 hours stratified by postmenstrual age.
Impact: Synthesizes three decades of evidence to refine risk stratification for infant postanesthesia apnea and supports neuraxial techniques as a risk-lowering strategy.
Clinical Implications: Use postmenstrual age as the primary determinant for postoperative monitoring duration (6–24 h) and consider neuraxial anesthesia when feasible to mitigate apnea risk.
Key Findings
- Median postanesthesia apnea incidence across studies was 7.6% (0–85%).
- Postmenstrual age and gestational age were dominant predictors; higher values reduced risk.
- Neuraxial anesthesia was associated with lower odds of apnea than general anesthesia (OR 0.236).
Methodological Strengths
- PRISMA-compliant systematic review with meta-regression and large literature base.
- Explored temporal trends and multiple clinical predictors including anesthesia type.
Limitations
- Heterogeneity in definitions, monitoring practices, and inclusion of varied study designs.
- Absence of uniform, patient-level data limits threshold precision; IPD meta-analysis pending.
Future Directions: Individual participant data meta-analysis to define precise postmenstrual age thresholds and to develop standardized monitoring/discharge protocols.
Former preterm and term infants are at risk for postanesthesia apnea, but the lack of uniform standards for monitoring and discharge criteria leads to inconsistent practice. The primary aim of this study was to identify major risk factors for postanesthesia apnea. This systematic review and meta-regression analysis used Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Agency for Healthcare Research and Quality guidelines. The literature search included English language case reports, case series, clinical studies, and clinical trials. Major databases were queried from inception to October 2025. A total of 6,191 articles underwent title and abstract screening, 491 underwent full-text screening, and 173 underwent detailed reviews. Data were extracted from 115 of 173 articles (98 studies, 17 case reports or series). Across studies (preterm or full term infants), the median incidence of apnea was 7.6% (range, 0 to 85%). Univariable meta-regression analysis (96 eligible articles) identified five significant predictors of apnea: gestational age, postmenstrual age at time of procedure, birth weight, procedure duration, and year of publication. Odds for apnea incidence decreased with later publication year, older gestational age at birth, older postmenstrual age at time of surgery, higher birth weight, and shorter procedure duration. A multivariable "best fitting model" (64 eligible articles) including publication year (1986 to 2025) and postmenstrual age (32 to 63 weeks) found a decrease in odds of apnea incidence with later publication year (odds ratio [OR], 0.936; CI, 0.91 to 0.964; P < 0.001) and higher postmenstrual age (OR, 0.889; CI, 0.828 to 0.954; P = 0.001). Recommended postanesthesia monitoring duration ranged from 6 to 24 h based on postmenstrual age. Meta-regression showed significantly lower apnea odds with neuraxial versus general anesthesia (OR, 0.236; CI, 0.094 to 0.592; P = 0.003). Postmenstrual age appears to be the strongest and most consistent risk factor for postanesthesia apnea; neuraxial anesthesia may reduce this risk. An individual participant data meta-analysis in a follow-up article will shed further light on the at-risk postmenstrual age threshold for increased risk and help refine monitoring recommendations for these vulnerable infants.
3. Efficacy and safety of N-methyl-d-aspartate receptor antagonists for preventing acute postoperative pain: A systematic review and network meta-analysis of randomized controlled trials.
Across 47 RCTs (n=3055), esketamine and high-dose dextromethorphan significantly reduced 24-hour postoperative pain; medium-dose dextromethorphan lowered morphine use, and magnesium sulfate reduced rescue analgesia needs. Evidence certainty was low to very low due to heterogeneity.
Impact: Provides a comparative, quantitative framework to prioritize NMDA antagonist–based adjuncts for acute postoperative pain while highlighting evidence gaps.
Clinical Implications: Consider esketamine or dextromethorphan (where available) as adjuncts to reduce early postoperative pain and opioid needs; magnesium sulfate may decrease rescue analgesic requirements. Apply cautiously given low certainty and availability constraints.
Key Findings
- Esketamine (MD −1.39) and high-dose dextromethorphan (MD −1.17) significantly reduced 24-h pain scores.
- Medium-dose dextromethorphan reduced 24-h morphine consumption (MD −10.50) and high-dose dextromethorphan prolonged time to first analgesic request.
- Magnesium sulfate significantly reduced rescue analgesic requirements; some regimens reduced PONV.
Methodological Strengths
- Network meta-analysis enabling indirect comparisons across multiple NMDA antagonist regimens.
- Pre-registered protocol and comprehensive database search with PICOS-driven selection.
Limitations
- Low to very low certainty for most outcomes due to heterogeneity and imprecision.
- Limited clinical availability of dextromethorphan constrains generalizability.
Future Directions: Head-to-head, adequately powered RCTs of prioritized regimens (e.g., esketamine doses) with standardized outcomes and safety monitoring.
BACKGROUND: Acute postoperative pain is highly prevalent following surgical procedures. Identifying N-methyl-d-aspartate (NMDA) receptor antagonists with potential for preventing acute postoperative pain is clinically critical, yet individual randomized controlled trials (RCT) often lack sufficient statistical power. Network meta-analysis mitigates this limitation by boosting statistical power, enabling comprehensive comparison of multiple interventions to identify the most effective therapeutic options for preventing acute postoperative pain. METHODS: We systematically searched Pubmed, Embase, Cochrane and MEDLINE databases for RCTs evaluating the efficacy of NMDA receptor antagonists in preventing acute postoperative pain. Studies were carefully selected based on the PICOS framework. We performed the network meta-analysis with R using the GeMTC and BUGSnet packages. The primary outcome was defined as the pain score at 24 h postoperatively. Secondary outcomes included morphine consumption at 24 h postoperatively, time to the first postoperative analgesic request, rescue analgesic requirements and incidence of postoperative nausea and vomiting (PONV). RESULTS: A total of 47 eligible RCTs involving 3055 participants were included in this analysis. In terms of reducing 24-h postoperative pain scores, esketamine (MD -1.39; 95% credible interval [Crl] -2.57 to -0.37), high-dose dextromethorphan (MD -1.17; 95% Crl -1.81 to -0.53) and medium-dose ketamine (MD -0.93; 95% Crl -1.74 to -0.08) exhibited significant effects. For secondary outcomes, medium-dose dextromethorphan (MD -10.50; 95% Crl -19.66 to -1.45) was optimal for reducing 24-h postoperative morphine consumption; high-dose dextromethorphan (MD 206.41; 95% Crl 24.39 to 394.30) effectively prolonged the time to first postoperative analgesic request; and magnesium sulphate (OR 6.91; 95% Crl 1.64 to 24.97) was the only intervention that significantly reduced rescue analgesic requirements. Medium-dose dextromethorphan (OR 15.32; 95% CrI 1.48 to 334.61) and ketamine administered via patient-controlled epidural analgesia (OR 5.88; 95% CrI 1.31 to 30.88) significantly reduced the incidence of PONV. CONCLUSIONS: Esketamine and high-dose dextromethorphan achieved clinically meaningful reductions in VAS pain scores at 24 h postoperatively. Additionally, medium-dose dextromethorphan decreased 24-h morphine consumption, high-dose dextromethorphan significantly prolonged the time to first analgesic request, and magnesium sulphate reduced rescue analgesia requirements. Medium-dose dextromethorphan and ketamine administered via patient-controlled epidural analgesia reduced the incidence of PONV. However, the increasingly limited clinical availability of dextromethorphan restricts the generalizability of our findings. Furthermore, the certainty of evidence for most outcomes was low to very low, mainly due to residual heterogeneity and imprecision, supporting the need for further high-quality studies. SYSTEMATIC REVIEW REGISTRATION: PROSPERO (CRD420251116678).